You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES

HIGHLIGHTS

EVENTS

Leading medical-scientific event on Hemophilia held in Trieste, Italy

Kedrion-organized congress put replacement therapy, personalization and access to care in the spotlight

read more 

EVENTS

Kedrion scientific symposium at the 2019 PNS Conference in Genoa, Italy

A chance for world Key Opinion Leaders to debate possible new therapies for the treatment of CIPN

read more 

PLASMA & BIOTHERAPIES

First patient enrolled and treated in Kedrion’s CARES10 clinical study

Phase 3 study to assess efficacy, safety and pharmacokinetics of a 10% IVIg in the treatment of adult PID patients

read more 
  1. PLASMA & BIOTHERAPIES - 24-06-2014

    Counterfeit RhoGAM Ultra-Filtered PLUS used for preventing HDN found in India

    Johnson & Johnson Limited has identified counterfeit RhoGAM Ultra-Filtered PLUS in the state of West Bengal and Uttar Pradesh in India. This issue does not involve any other product manufactured or distributed by Ortho Clinical Diagnostics or Kedrion Biopharma India Pvt. Ltd.

    read more 
  2. CORPORATE - 20-05-2014

    Kedrion, one of Italy’s most innovative companies in 2014

    The MIT Technology Review Italia’s award given in Bologna in mid-May

    read more 
  3. CORPORATE - 17-04-2014

    5-year unrated EUR 300 million bond successfully launched

    The bonds have been placed with leading international institutional investors and will be listed on the Irish Stock Exchange

    read more 
  4. CORPORATE - 16-04-2014

    Kedrion Group approves 2013 financial statements

    Achieved results of 425 million euros turnover and a 25% profitability

    read more 

Pages

For more information please contact: pressoffice@kedrion.com